PDS Biotechnology Corp Gain (Loss) on Extinguishment of Debt
PDS Biotechnology Corp (PDSB) reported Gain (Loss) on Extinguishment of Debt of -$2.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-13
- PDS Biotechnology Corp gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was -$354.17K.
- PDS Biotechnology Corp gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was -$752.84K.
- PDS Biotechnology Corp gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- PDS Biotechnology Corp gain (loss) on extinguishment of debt for fiscal 2025 was -$1.11M.
- PDS Biotechnology Corp gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- PDS Biotechnology Corp gain (loss) on extinguishment of debt for fiscal 2019 was $0.00.
- PDS Biotechnology Corp gain (loss) on extinguishment of debt for fiscal 2018 was -$185.80K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.66M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | -$354.17K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$1.11M derived: sum of 2 quarters · filed 2026-03-30 | -$1.11M 10-K · filed 2026-03-30 | |
| 2025-09-30 | -$752.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$752.84K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-03-27 | |||
| 2018-12-31 | -$185.80K 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |